Drug to reduce antibiotic-resistant gut bacteria
Part of Infections clinical trials.
This Phase 2 study tests whether an investigational treatment can help clear or reduce antibiotic-resistant bacteria living in the gut. It may help prevent these germs from causing future infections by targeting specific resistant bacteria found on stool or rectal swabs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 years or older and able to sign consent (or have a legal representative who can).
- Have a positive stool or rectal swab for one of these resistant bacteria: CRE, VRE, ESBL, drug-resistant Acinetobacter, and/or drug-resistant Pseudomonas.
- Be able to follow study instructions, including swallowing capsules.
- Stop taking “systemic” (whole-body) antibiotics at least 1 day before the study starts (Day 0) and avoid antibiotics during the study if medically possible.
- If you can get pregnant or father a child, agree to reliable birth control during the study and for the required time after the last dose; do not plan pregnancy during the study.
- Agree to stop probiotics or other gut “microbiome restoration” treatments at least 1 day before Day 0 and during the whole study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a treatment made from healthy donor stool (called microbiota therapy) given as an enema or through a feeding tube. It aims to help people who carry resistant bacteria that are hard to treat, by reducing or clearing those bacteria from the gut.
This trial tests whether taking capsules containing processed healthy donor stool (fecal microbiota transplant) can safely remove certain drug-resistant bacteria (like CRE, ESBL-E, and VRE) from your intestines. It may be an option for people who have these bacteria in their stool but are not currently being treated with antibiotics.
This study tests whether a new treatment called BM111 can safely clear two types of antibiotic-resistant bacteria (CRE and VRE) that live in your intestines without causing infection. You'd provide stool samples over several weeks to see if the bacteria levels drop.
This trial tests whether a stool (fecal) transplant from a screened donor can help remove antibiotic-resistant gut bacteria (MDRO) that keep coming back in your stool tests. It aims to reduce colonization that makes follow-up and treatment harder.
This Phase 3 study tests whether a fecal microbiota transplant (FMT) can eliminate hard-to-treat bacteria in the gut, such as ESBL or carbapenem-resistant bacteria. If it works, it may reduce future infections and antibiotic-resistant illness.
This study tests a stool-based treatment (fecal microbiota treatment) to help remove “carbapenem-resistant” bacteria living in the gut. If you carry these bacteria without being sick, the goal is to reduce or stop that colonization.
Hear when a new Intestinal Multi-drug Resistant Organism Colonization trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.